A breast cancer drug failed its largest clinical test, a result that could limit how widely the medicine is prescribed. First-line therapy is the term for the initial drug doctors try after a patient's cancer advances, before other options are substituted or added. That is what AstraZeneca's camizestrant was being tested for: the drug, taken as a pill alongside another medicine, did not keep cancer from progressing longer than standard care in the SERENA-4 trial, AstraZeneca said Friday.
What the trial was testing
SERENA-4 enrolled patients with ER-positive, HER2-negative advanced breast cancer who had not yet received systemic therapy for their advanced disease. In plain terms: these were patients with advanced tumors at the starting line of drug treatment. Systemic therapy refers to medications that travel through the bloodstream to reach cancer throughout the body, as distinct from local approaches such as surgery or radiation. ER-positive means the tumor is fueled by estrogen receptors. HER2-negative means it lacks a second growth-driving protein; tumors that carry HER2 typically require a different class of drugs.
Researchers tracked how long patients went without their cancer worsening. On that measure, camizestrant taken alongside a companion drug did not outperform standard treatment.
What the drug is already cleared to do
Camizestrant holds a U.S. approval under the brand name Etcamah, granted earlier this month. That approval came through what regulators call accelerated approval, a designation that allows a drug to reach patients sooner than the standard review timeline. The approved use is narrower than what SERENA-4 was testing: it covers patients whose tumors have already developed a specific mutation, a genetic change signaling that the cancer is building resistance to a prior drug. Those patients were further along in treatment than the patients SERENA-4 enrolled.
AstraZeneca said the trial failure could limit the medicine's overall use. A positive result could have opened a much larger market for the drug. Its reach now stays with patients who have already shown that resistance mutation in their tumor.